Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21531048 | 1.00 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL23219574 | 1.00 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL21531043 | 0.85 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL23641803 | 0.85 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL23219606 | 0.85 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL21531042 | 0.85 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL17312873 | 0.84 | RIPK1 (0.73) | RIPK1 | |
| SCHEMBL17312870 | 0.84 | RIPK1 (0.73) | RIPK1 | |
| SCHEMBL23219613 | 0.84 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL21531061 | 0.84 | RIPK1 (1.00) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139494-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-13 | — | — | US | claimed |
| EP-4055021-B1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIGEL PHARMACEUTICALS INC (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4025574-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250092057-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIGEL PHARMACEUTICALS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20240368119-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11919890-B2 | RIP1 inhibitory compounds and methods for making and using the same | ;Eli Lilly and Company (US) | 2024-03-05 | — | — | US | disclosed |
| EP-3788045-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-4025574-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20210214347-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210214347-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210139494-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-10975064-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10975064-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20210070743-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2021046407-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| EP-3788045-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190337934-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | MIDCAP FINANCIAL TRUST | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919890-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-20240368119-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-20210214347-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-20250092057-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-20210139494-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-20190337934-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-10975064-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-20210070743-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.